Showing results (21-30 of 108) with videos related to
Sort By:
Pageof 11
International Journal of Radiation Oncology, Biology, Physics|January 14, 2014
Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cellsArun Azad, Patricia Bukczynska, Susan Jackson, et al.Dalton Transactions (Cambridge, England : 2003)|April 17, 2008
Inclusion complexes of the antitumour metallocenes Cp(2)MCl(2) (M = Mo, Ti) with cucurbit[n]urilsDamian P Buck, P Manohari Abeysinghe, Carleen Cullinane, et al.Journal of Inorganic Biochemistry|June 14, 2002
Preparation and cell growth inhibitory activity of [PtR(2)L(2)] (R=polyfluorophenyl, L(2)=diene, cyclohexane-1,2-diamine (chxn) or cis-(dimethyl sulfoxide)(2)) and the X-ray crystal structure of [Pt(C(6)F(5))(2)(cis-chxn)]Carleen Cullinane, Glen B Deacon, Penny R Drago, et al.Chemical Communications (Cambridge, England)|June 5, 2004
Multi-nuclear platinum complexes encapsulated in cucurbit[n]uril as an approach to reduce toxicity in cancer treatmentNial J Wheate, Anthony I Day, Rodney J Blanch, et al.Molecular Cancer Therapeutics|May 6, 2010
Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor modelCarleen Cullinane, Anthony Natoli, Yorlon Hui, et al.The Analyst|November 21, 2018
ATR-FTIR spectroscopy shows changes in ovarian cancer cells after incubation with novel organoamidoplatinum(ii) complexesKhansa Al-Jorani, Anja Rüther, Rukshani Haputhanthri, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 18, 2010
18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor modelNicolas Aide, Kathryn Kinross, Carleen Cullinane, et al.Molecular Imaging and Biology|July 16, 2010
A dual radiologic contrast agent protocol for 18F-FDG and 18F-FLT PET/CT imaging of mice bearing abdominal tumorsNicolas Aide, Kathryn Kinross, Jean-Mathieu Beauregard, et al.Theranostics|September 29, 2023
A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177Lutetium-DOTA-octreotate radionuclide therapyKelly Waldeck, Jessica Van Zuylekom, Carleen Cullinane, et al.European Journal of Nuclear Medicine and Molecular Imaging|August 16, 2014
Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedsideJeremy Lewin, Carleen Cullinane, Tim Akhurst, et al.Pageof 11